Market Analysts see Johnson & Johnson [JNJ] gaining to $183. Time to buy?

Related

Johnson & Johnson [NYSE: JNJ] jumped around 0.99 points on Monday, while shares priced at $175.83 at the close of the session, up 0.57%. The company report on March 15, 2022 that Johnson & Johnson to Host Investor Conference Call on First-Quarter Results.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 19th to review first-quarter results. Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Jessica Moore, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson’s executive team.

Investors and other interested parties can access the webcast/conference call in the following ways:.

Johnson & Johnson stock is now 2.78% up from its year-to-date (YTD) trading value. JNJ Stock saw the intraday high of $177.16 and lowest of $174.32 per share. The company’s 52-week high price is 179.92, which means current price is +12.91% above from all time high which was touched on 03/21/22.

Compared to the average trading volume of 7.79M shares, JNJ reached a trading volume of 7509321 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Johnson & Johnson [JNJ]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for JNJ shares is $186.53 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on JNJ stock is a recommendation set at 2.10. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Bernstein have made an estimate for Johnson & Johnson shares, keeping their opinion on the stock as Mkt Perform, with their previous recommendation back on March 16, 2022. While these analysts kept the previous recommendation, BofA Securities raised their target price to Neutral. The new note on the price target was released on March 02, 2022, representing the official price target for Johnson & Johnson stock. Previously, the target price had yet another raise to $161, while Goldman analysts kept a Neutral rating on JNJ stock. On December 15, 2021, analysts increased their price target for JNJ shares from 192 to 195.

The Average True Range (ATR) for Johnson & Johnson is set at 3.44, with the Price to Sales ratio for JNJ stock in the period of the last 12 months amounting to 4.99. The Price to Book ratio for the last quarter was 6.25, with the Price to Cash per share for the same quarter was set at 11.89. Price to Free Cash Flow for JNJ in the course of the last twelve months was 53.58 with Quick ratio for the last quarter at 1.10.

How has JNJ stock performed recently?

Johnson & Johnson [JNJ] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 2.41. With this latest performance, JNJ shares gained by 5.80% in over the last four-week period, additionally plugging by 7.34% over the last 6 months – not to mention a rise of 9.55% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for JNJ stock in for the last two-week period is set at 61.47, with the RSI for the last a single of trading hit 64.23, and the three-weeks RSI is set at 59.27 for Johnson & Johnson [JNJ]. The present Moving Average for the last 50 days of trading for this stock 168.98, while it was recorded at 175.63 for the last single week of trading, and 167.45 for the last 200 days.

Johnson & Johnson [JNJ]: Deeper insight into the fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Johnson & Johnson [JNJ] shares currently have an operating margin of +26.11 and a Gross Margin at +68.14. Johnson & Johnson’s Net Margin is presently recorded at +22.27.

Return on Equity for this stock inclined to 30.41, with Return on Assets sitting at 11.70.

Johnson & Johnson’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.10 and a Current Ratio set at 1.30.

Earnings analysis for Johnson & Johnson [JNJ]

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for JNJ. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Johnson & Johnson go to 6.05%.

Insider trade positions for Johnson & Johnson [JNJ]

There are presently around $319,239 million, or 70.30% of JNJ stock, in the hands of institutional investors. The top three institutional holders of JNJ stocks are: VANGUARD GROUP INC with ownership of 234,782,632, which is approximately 0.558% of the company’s market cap and around 0.10% of the total institutional ownership; BLACKROCK INC., holding 200,021,352 shares of the stock with an approximate value of $34.97 billion in JNJ stocks shares; and STATE STREET CORP, currently with $25.3 billion in JNJ stock with ownership of nearly 1.753% of the company’s market capitalization.

Positions in Johnson & Johnson stocks held by institutional investors increased at the end of January and at the time of the January reporting period, where 1,945 institutional holders increased their position in Johnson & Johnson [NYSE:JNJ] by around 56,592,716 shares. Additionally, 1,437 investors decreased positions by around 49,834,145 shares, while 300 investors held positions by with 1,719,468,116 shares. The mentioned changes placed institutional holdings at 1,825,894,977 shares, according to the latest SEC report filing. JNJ stock had 375 new institutional investments in for a total of 10,512,574 shares, while 87 institutional investors sold positions of 3,387,439 shares during the same period.

[class^="wpforms-"]
[class^="wpforms-"]